Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Immunotherapy

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Front Immunol.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S

doi: 10.3389/fimmu.2019.01613.

T Cells

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Lancet

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group.

doi: 10.1016/S0140-6736(20)32334-5

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Curr Res Transl Med.

Ghobadi A

doi: 10.1016/

Melanoma and Skin Cancer

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

JAMA Dermatol.

Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T

doi: 10.1001/jamadermatol.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

T Cells

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Lancet Haematol

Gudiol C, Lewis RE, Strati P, Kontoyiannis DP

doi: 10.1016/S2352-3026(20)30376-8

Melanoma and Skin Cancer

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Melanoma Res

Lauwyck J, Beckwée A, Santens A, Schwarze JK, Awada G, Vandersleyen V, Aspeslagh S, Neyns B

doi: 10.1097/CMR.0000000000000748

COMMENTED

Melanoma and Skin Cancer

Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy

JAMA Dermatol.

Sun L, Chin RI, Gastman B, Thorstad W, Yom SS, Reddy CA, Nussenbaum B, Wang SJ, Knackstedt T, Vidimos AT, Koyfman SA, Manyam BV

doi: 10.1001/jamadermatol.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Ann Rheum Dis.

Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T

doi: 10.1136/annrheumdis-2020-217139.

Related content

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors